Influence of initial treatment modality on long-term control of chronic idiopathic urticaria

PLoS One. 2013 Jul 23;8(7):e69345. doi: 10.1371/journal.pone.0069345. Print 2013.

Abstract

Background: Chronic idiopathic urticaria (CIU) is a common cutaneous disorder but the influence of initial treatment modality on long-term control is not known. The aim of this study was to evaluate clinical features, and the influence of initial treatment modality on long-term control.

Methods and results: 641 CIU patients were enrolled from the allergy clinic in a tertiary referral hospital. Disease duration, aggravating factors and treatment modality at each visit were evaluated. Times required to reach a controlled state were analyzed according to initial treatment modality, using Kaplan-Meier survival curves, the Cox proportional-hazards model, and propensity scores. Female to male ratio was 1.7: 1; mean age at onset was 40.5 years. The most common aggravating factors were food (33.5%), stress (31.5%) and fatigue (21.6%). Most patients (82.2%) used H1-antihistamines alone as initial treatment while 17% used a combination treatment with oral corticosteroids. There was no significant difference in the time taken to reach a controlled state between patients treated with single vs multiple H1-antihistamines or between those who received H1-antihistamine monotherapy vs. a combination therapy with oral corticosteroids.

Conclusion: The time required to control CIU is not reduced by use of multiple H1-antihistamines or oral corticosteroids in the initial treatment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Adrenal Cortex Hormones / administration & dosage
  • Adrenal Cortex Hormones / therapeutic use
  • Adult
  • Chronic Disease
  • Demography
  • Drug Prescriptions
  • Drug Therapy, Combination
  • Female
  • Histamine H1 Antagonists / therapeutic use
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Practice Patterns, Physicians'
  • Proportional Hazards Models
  • Urticaria / drug therapy
  • Urticaria / prevention & control*
  • Urticaria / therapy*

Substances

  • Adrenal Cortex Hormones
  • Histamine H1 Antagonists

Grants and funding

This study was supported by a grant (2011-420) from the Asan Institute for Life Sciences, Seoul, Korea. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.